Zealand Pharma Gets Positive EU Opinion For Zeydovio In Short Bowel Syndrome

Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.

Jefferies downgraded Zealand Pharma (ZELA) from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing no near-term value catalysts in 2H 2026. It reduced the probability of success for survodutide to 40% from 60% due to tolerability concerns after Phase III data. Shares fell about 2% with no Zealand-specific news.

Jefferies downgraded Zealand Pharma A/S to Hold from Buy and cut its price target to DKK320 from DKK505, citing fewer near-term catalysts. The firm lowered survodutide Phase III success odds to 40% from 60% after disappointing data. Zealand shares fell 2.7% to DKK273.40 in Copenhagen.

Ultragenyx Pharmaceutical (RARE) shares rose 9% this week after FDA approved Fayuvi, a gene therapy for Sanfilipso syndrome, and raised price targets. The stock rebounded from a 44% drop after its Angelman syndrome trial failed. Analysts see value in its $1.4B market cap and new therapies. RARE plans to sell priority review vouchers for ~$400M.

DoorDash (DASH) agreed to pay $131.5m to settle a NYC probe into worker pay, including $12.3m for underpaid couriers, $83m over pay calculation disputes, and $16.7m in fines. The settlement affects 264,000 Dashers. DoorDash reported Q2 2026 net income of $200m, with revenue at $4.45bn. Shares traded at $197.05 as of 22 September 2026, down 14.32% over 20 days.

Cinema United, a movie theater trade association, praised a settlement in the Warner Bros. Discovery acquisition by Paramount, noting it includes increased film production, theatrical exclusivity, and catalog access. The deal requires Paramount to release a set number of films widely over five years and prohibits premium VOD marketing before a 45-day theatrical window. Cinema United had previously warned about the potential negative impacts of such mergers on theaters and local economies.